Caris Life Sciences last week expanded its Caris Target Now molecular profiling test to include ovarian cancer.
"Caris Target Now molecular profiling examines the unique genetic and molecular makeup of each patient's tumor so that treatment options may be matched to each patient individually," the company said in a statement.
Caris claims that Target Now, which is also available for lung, breast, and prostate cancer, is currently being used by more than 1,000 patients per month.
According to the company, Caris Target Now is for doctors whose ovarian cancer patients have progressed on platinum-based therapy and for patients who need third-line treatment options.
The molecular profiling test analyzes genetic and molecular alterations in tumors in order to recommend a treatment strategy that is most likely to benefit the patient. The profiling system first conducts immunohistochemistry tests to measure cancer cell proteins and, depending on the patient's specific disease characteristics, runs additional tests to gauge gene expression, gene mutations, and copy number variation via PCR, FISH, sequencing, or microarray tests.
"Caris takes the results from each test and applies the published findings from thousands of the world's leading cancer researchers," the company states on its website describing Caris Target Now. "Based on this analysis, Caris Target Now identifies potential therapies for patients and their treating physicians to discuss."
According to the company, the Target Now test is meant to help patients who have tried all other standard-of-care treatments or if the doctor has outstanding questions about the right therapeutic strategy for a particular patient. Tests performed within the Caris Target Now profiling system are conducted in the company's CLIA-certified laboratory.